NO20074057L - 2,4-Diaminopyridopyrimidine derivatives and their use as mTOR inhibitors - Google Patents

2,4-Diaminopyridopyrimidine derivatives and their use as mTOR inhibitors

Info

Publication number
NO20074057L
NO20074057L NO20074057A NO20074057A NO20074057L NO 20074057 L NO20074057 L NO 20074057L NO 20074057 A NO20074057 A NO 20074057A NO 20074057 A NO20074057 A NO 20074057A NO 20074057 L NO20074057 L NO 20074057L
Authority
NO
Norway
Prior art keywords
diaminopyridopyrimidine
derivatives
mtor inhibitors
nitrogen
attached form
Prior art date
Application number
NO20074057A
Other languages
Norwegian (no)
Inventor
Xiao-Ling Fan Cockcroft
Sylvie Gomez
Keith Allan Menear
Marc Geoffrey Hummersone
Peter Edwards
Vincent Junior Ming Lai Loh
Graeme Caameron Murray Smith
Original Assignee
Kudos Pharm Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB0503961.5A external-priority patent/GB0503961D0/en
Application filed by Kudos Pharm Ltd filed Critical Kudos Pharm Ltd
Publication of NO20074057L publication Critical patent/NO20074057L/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Oncology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Transplantation (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Communicable Diseases (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

Forbindelser med formel I: og isomerer, salter, solvater, kjemisk beskyttede former og prodrugs derav, hvor én av X1, X2 og X3 er N og de andre er CH; RN1 og RN2 danner sammen med nitrogenatomet de er bundet til, en nitrogen-holdig, heterocyklisk ring som har fra 4 til 8 ringatomer; RN3 og RN4 danner sammen med nitrogenatomet de er bundet til, en nitrogen-holdig, heterocyklisk ring som har fra 4 til 8 ringatomer, og anvendelsen av disse ved behandling av sykdommer som lindres ved inhibering av mTOR.Compounds of formula I: and isomers, salts, solvates, chemically protected forms and prodrugs thereof, wherein one of X1, X2 and X3 is N and the other is CH; RN1 and RN2 together with the nitrogen atom to which they are attached form a nitrogen-containing heterocyclic ring having from 4 to 8 ring atoms; RN3 and RN4 together with the nitrogen atom to which they are attached form a nitrogen-containing heterocyclic ring having from 4 to 8 ring atoms, and their use in the treatment of diseases which are alleviated by inhibition of mTOR.

NO20074057A 2005-02-25 2007-08-07 2,4-Diaminopyridopyrimidine derivatives and their use as mTOR inhibitors NO20074057L (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US65617805P 2005-02-25 2005-02-25
GBGB0503961.5A GB0503961D0 (en) 2005-02-25 2005-02-25 Compounds
US74240305P 2005-12-05 2005-12-05
PCT/GB2006/000671 WO2006090169A1 (en) 2005-02-25 2006-02-24 2,4-diamino-pyridopyrimidine derivatives and their use as mtor inhibitors

Publications (1)

Publication Number Publication Date
NO20074057L true NO20074057L (en) 2007-09-17

Family

ID=36282842

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20074057A NO20074057L (en) 2005-02-25 2007-08-07 2,4-Diaminopyridopyrimidine derivatives and their use as mTOR inhibitors

Country Status (9)

Country Link
EP (1) EP1871377A1 (en)
JP (1) JP2008531538A (en)
KR (1) KR20070113252A (en)
AU (1) AU2006217744A1 (en)
CA (1) CA2599212A1 (en)
IL (1) IL184901A0 (en)
MX (1) MX2007010401A (en)
NO (1) NO20074057L (en)
WO (1) WO2006090169A1 (en)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2006261607A1 (en) 2005-06-24 2006-12-28 Gilead Sciences, Inc. Pyrido(3,2-d)pyrimidines and pharmaceutical compositions useful for treating hepatitis C.
US8338435B2 (en) * 2006-07-20 2012-12-25 Gilead Sciences, Inc. Substituted pyrido(3,2-D) pyrimidines and pharmaceutical compositions for treating viral infections
SI2057156T1 (en) * 2006-08-23 2017-06-30 Kudos Pharmaceuticals Limited 2-methylmorpholine pyrido-,pyrazo- and pyrimido-pyrimidine derivatives as mtor inhibitors
TW200840584A (en) 2006-12-26 2008-10-16 Gilead Sciences Inc Pyrido(3,2-d)pyrimidines useful for treating viral infections
EP2318377B1 (en) 2008-07-31 2013-08-21 Genentech, Inc. Pyrimidine compounds, compositions and methods of use
US9540322B2 (en) 2008-08-18 2017-01-10 Yale University MIF modulators
US9643922B2 (en) 2008-08-18 2017-05-09 Yale University MIF modulators
BRPI0917394A2 (en) * 2008-08-18 2019-09-24 Univ Yale mif modulators
US8110578B2 (en) * 2008-10-27 2012-02-07 Signal Pharmaceuticals, Llc Pyrazino[2,3-b]pyrazine mTOR kinase inhibitors for oncology indications and diseases associated with the mTOR/PI3K/Akt pathway
KR20110115160A (en) * 2009-02-12 2011-10-20 메르크 세로노 에스. 에이. 2-morpholino-pyrido[3,2-d]pyrimidines
EP2417138B1 (en) * 2009-04-09 2019-11-27 Merck Sharp & Dohme Corp. Pyrazolo[1, 5-a]pyrimidine derivatives as mtor inhibitors
US8242260B2 (en) 2009-08-28 2012-08-14 Novartis Ag Compounds and compositions as protein kinase inhibitors
CA2774769A1 (en) 2009-09-30 2011-04-07 Schering Corporation Novel compounds that are erk inhibitors
JP2013509444A (en) 2009-10-30 2013-03-14 アリアド・ファーマシューティカルズ・インコーポレイテッド Cancer treatment method and therapeutic composition
JP5572715B2 (en) 2009-11-12 2014-08-13 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト N-7 substituted purines and pyrazolopyrimidine compounds, compositions and methods of use
CN102711766B (en) 2009-11-12 2014-06-04 霍夫曼-拉罗奇有限公司 N-9-substituted purine compounds, compositions and methods of use
WO2011067356A2 (en) 2009-12-03 2011-06-09 Novartis Ag Polymorphs of a mek inhibitor
WO2011067348A2 (en) 2009-12-03 2011-06-09 Novartis Ag Mek inhibitor salts and solvates thereof
WO2011097333A1 (en) 2010-02-03 2011-08-11 Signal Pharmaceuticals, Llc Identification of lkb1 mutation as a predictive biomarker for sensitivity to tor kinase inhibitors
MX2012011341A (en) 2010-03-30 2012-11-12 Novartis Ag Pkc inhibitors for the treatment of b-cell lymphoma having chronic active b-cell-receptor signalling.
CA2800327A1 (en) 2010-04-13 2011-10-20 Novartis Ag Combination comprising a cyclin dependent kinase 4 or cyclin dependent kinase 6 (cdk4/6) inhibitor and an mtor inhibitor for treating cancer
AU2011268906A1 (en) 2010-06-25 2013-01-31 Novartis Ag Heteroaryl compounds and compositions as protein kinase inhibitors
EP2615916B1 (en) 2010-09-16 2017-01-04 Merck Sharp & Dohme Corp. Fused pyrazole derivatives as novel erk inhibitors
US20130158023A1 (en) 2011-08-03 2013-06-20 Signal Pharmaceuticals, Llc Identification of gene expression as a predictive biomarker for lkb1 status
EA030253B1 (en) * 2012-09-28 2018-07-31 Кэнсэр Ресерч Текнолоджи Лимитед Azaquinazoline inhibitors of atypical protein kinase c
AU2013203714B2 (en) 2012-10-18 2015-12-03 Signal Pharmaceuticals, Llc Inhibition of phosphorylation of PRAS40, GSK3-beta or P70S6K1 as a marker for TOR kinase inhibitory activity
CN103588792B (en) * 2013-03-04 2016-03-23 中国科学院上海药物研究所 Pyridopyrimidine or pyrimido-pyrimidine compounds, its preparation method, medical composition and its use
TW201521725A (en) 2013-04-17 2015-06-16 Signal Pharm Llc Methods for treating cancer using TOR kinase inhibitor combination therapy
CN105392499B (en) 2013-04-17 2018-07-24 西格诺药品有限公司 The combination treatment for including TOR kinase inhibitors and cytidine analog for treating cancer
US9474757B2 (en) 2013-04-17 2016-10-25 Signal Pharmaceuticals, Llc Methods for treating cancer using TOR kinase inhibitor combination therapy
KR102459285B1 (en) 2013-04-17 2022-10-27 시그날 파마소티칼 엘엘씨 PHARMACEUTICAL FORMULATIONS, PROCESSES, SOLID FORMS AND METHODS OF USE RELATING TO 1-ETHYL-7-(2-METHYL-6-(1H-1,2,4-TRIAZOL-3-YL)PYRIDIN-3-YL)-3,4-DIHYDROPYRAZINO[2,3-b]PYRAZIN-2(1H)-ONE
UA119538C2 (en) 2013-04-17 2019-07-10 Сігнал Фармасьютікалз, Елелсі Treatment of cancer with dihydropyrazino-pyrazines
AU2014254058B2 (en) 2013-04-17 2019-06-06 Signal Pharmaceuticals, Llc Combination therapy comprising a Dihydropyrazino-Pyrazine Compound and an androgen receptor antagonist for treating prostate cancer
KR102221029B1 (en) 2013-04-17 2021-02-26 시그날 파마소티칼 엘엘씨 Treatment of cancer with dihydropyrazino-pyrazines
CN107474051B (en) 2013-05-29 2020-10-30 西格诺药品有限公司 Pharmaceutical compositions of dihydropyrazinopyrazine compounds, solid forms thereof and their use
MX368311B (en) * 2013-09-30 2019-09-27 Korea Res Inst Chemical Tech Novel triazolopyrazine derivative and use thereof.
NZ714742A (en) 2014-04-16 2017-04-28 Signal Pharm Llc Solid forms of 1-ethyl-7-(2-methyl-6-(1h-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1h)-one, compositions thereof and methods of their use
WO2015160880A1 (en) 2014-04-16 2015-10-22 Signal Pharmaceuticals, Llc SOLID FORMS COMPRISING 1-ETHYL-7-(2-METHYL-6-(1H-1,2,4-TRIAZOL-3-YL) PYRIDIN-3-YL)-3,4-DIHYDROPYRAZINO(2,3-b)PYRAZIN-2(1H)-ONE, AND A COFORMER, COMPOSITIONS AND METHODS OF USE THEREOF
JOP20190257A1 (en) * 2017-04-28 2019-10-28 Novartis Ag 6-6 fused bicyclic heteroaryl compounds and their use as lats inhibitors
IL271491B2 (en) 2017-06-22 2023-09-01 Celgene Corp Treatment of hepatocellular carcinoma characterized by hepatitis b virus infection
CN115304600B (en) * 2022-09-29 2023-01-13 北京鑫开元医药科技有限公司 mTOR inhibitor, preparation method and application

Also Published As

Publication number Publication date
JP2008531538A (en) 2008-08-14
IL184901A0 (en) 2007-12-03
CA2599212A1 (en) 2006-08-31
WO2006090169A1 (en) 2006-08-31
AU2006217744A1 (en) 2006-08-31
MX2007010401A (en) 2008-02-19
EP1871377A1 (en) 2008-01-02
KR20070113252A (en) 2007-11-28

Similar Documents

Publication Publication Date Title
NO20074057L (en) 2,4-Diaminopyridopyrimidine derivatives and their use as mTOR inhibitors
TW200640462A (en) Compounds
NO20073791L (en) Pyrazolylaminopyridine derivatives useful as kinase inhibitors
TN2009000107A1 (en) New sulfonamide derivatives as bradykinin antagonists
NO20091889L (en) Inhibitors of spiroketone acetyl-CoA carboxylase
PE20140863A1 (en) BENZENE COMPOUNDS REPLACED WITH ARYL OR HETEROARYL
DE602006007012D1 (en) PYRIDINE DERIVATIVES AS DIPEPTEDYL-PEPTIDASE INHIBITORS
NO20082346L (en) Hydrazone derivatives and uses thereof
NO20085385L (en) Thiazole compounds such as cannabinoid receptor ligands and uses thereof
EP1867331A4 (en) Triazole derivative and the use thereof
NO20092770L (en) Novel aminopyrimidine derivatives as PLK1 inhibitors
MX2009012283A (en) Nitrogen-containing heterocyclic derivative having 11 î²-hydroxysteroid dehydrogenase type i inhibitory activity.
NO20092286L (en) Nitrogen-containing heterocyclic compounds and their use
NZ599040A (en) 2,4-disubstituted pyrido[4,3-d]pyrimidin-5(6h)-one compounds for selective inhibitors of lrrk2 and syk kinases
TW200728260A (en) Substituted-(quinazolinyl)phenyl thiophenyl-sulfonylureas, methods for making and intermediates thereof
TW200833675A (en) Nicotinamide derivatives
MX2012003499A (en) Lysine specific demethylase-1 inhibitors and their use.
TW200626610A (en) Analogs of 17-hydroxywortmannin as PI3K inhibitors
RS53839B1 (en) Spirocycles as inhibitors of 11-beta hydroxyl steroid dehydrogenase type 1
NO20091265L (en) Pyrrolopyrazine as Syk kinase inhibitor
NO20081217L (en) New benzothiazole derivatives
NO20085269L (en) 2-thioxanthine derivatives which act as MPO inhibitors
TW201129564A (en) Diphenylpyrazolopyridine derivatives, preparation thereof and therapeutic use thereof
NO20062021L (en) Redirected pentanols, their methods of preparation, and their use as antiflogistics
UA88329C2 (en) Dna-pk inhibitors

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application